Abstract
Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease
that affects an estimated 2 million people in the United States and an
estimated 20 million individuals worldwide. The RA treatment market has
undergone significant changes over the past 5-10 years with the introduction
of biologic, Disease Modifying Antirheumatic Drugs (DMARDs) - specifically,
the Tumor Necrosis Factor-alpha (TNF-α) class of protein therapeutics.
Products such as Enbrel (etanercept), Remicade (infliximab), and Humira
(adalimumab) have established themselves as the standard of care in RA
patients failing to respond to conventional DMARDs and in turn have generated
significant financial windfalls for their developers and marketers.
The success of the TNF-α class of therapeutics, in conjunction with the
large patient population they address, has created an explosion in R&D
activity for new biologic and small-molecule treatments. As of January 2009,
Austin Research Group has identified and is tracking 96 active programs in
clinical trials.
Austin Research Group' s Therapeutic Clinical Intelligence (TCI) report
provides clients with an exhaustive compilation and in-depth assessment of the
entire clinical R&D competitive landscape for RA therapeutics.
This TCI report is the most comprehensive assessment of the RA competitive
landscape published to date. The report contains more than 300 pages of
detailed intelligence, analysis, and commentary on the clinical profiles 96
active RA programs from market to phase 1 that have the potential to alter the
market dynamics in RA over the next 5-10 years.
This actionable deliverable captures detailed intelligence on competitive
clinical programs in a ready-to-use format, enabling fast analysis without
wading through voluminous text and white space common in other therapeutic
area publications.
Table of Contents
Section 1 - Executive Summary6
Section 2 - Market Leaders & Near-Term Competitors 13
- Enbrel (etanercept)16
- Remicade (infliximab)26
- Humira (adalimumab) 36
- Rituxan (rituximab) 46
- Orencia (abatacept) 56
- Actemra (tocilizumab) 69
- Cimzia (certolizumab pegol) 96
- Simponi (Golimumab) 104
- Ocrelizumab115
- Arzerra (ofatumumab) 122
- CP-690,550128
Section 3: Mid-Stage Competition to Watch 142
- TRU-015143
- INCB018424 157
- R788 (fostamatinib)164
- Belimumab (LymphoStat-B)172
- AZD9056 175
- canakinumab (ACZ885) 180
Section 4 a: Phase 2 Pipeline: Biologics 183
- LY-2127399 184
- CNTO-136 187
- ALD-518 189
- ART-621 191
- MDX-1100194
- BT-061197
- T-1h-mAb (h-T1)199
- 315234 200
- KB-002/KB-003 203
- LY-2189102205
- AIN-457207
- Atacicept 209
- MM-093 214
Section 4 b: Phase 2 Pipeline: Small-Molecule (Orals) 219
- 681323220
- 856553225
- BMS-582949 227
- PH-797804 230
- KC-706 233
- RWJ-445380 234
- AZD5672 236
- CH-1504 238
- 4SC-101 243
- Panaclar 245
- DE-096 247
- ARRY-162 248
- Apilimod257
- TAK-783259
- CF-101 261
- SSR-150106 265
- CE-224535 267
- Rabeximod 270
- PG-760564 272
- Rimacalib274
- PMI-001276
- K-832278
- VX-702 279
- LX-2931 282
- HE-3286 287
Section 5: On the Radar: Overview of Phase 1 RA Programs 289
- Small Molecules 290
- Biologics293
- Undisclosed Programs297
Section 6: Discontinued RA Programs298
Section 7 - Appendix300
